select a format

Single User License
USD 2000 INR 128080
Site License
USD 4000 INR 256160
Corporate User License
USD 6000 INR 384240

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline Review, H2 2015

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline Review, H2 2015


  • Products Id :- GMDHC7213IDB
  • |
  • Pages: 249
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline Review, H2 2015', provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Plaque Psoriasis (Psoriasis Vulgaris) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Plaque Psoriasis (Psoriasis Vulgaris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Plaque Psoriasis (Psoriasis Vulgaris) Overview 10

Therapeutics Development 11

Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris)-Overview 11

Plaque Psoriasis (Psoriasis Vulgaris)-Therapeutics under Development by Companies 12

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Plaque Psoriasis (Psoriasis Vulgaris)-Products under Development by Companies 20

Plaque Psoriasis (Psoriasis Vulgaris)-Companies Involved in Therapeutics Development 25

3SBio Inc. 25

Amgen Inc. 26

AstraZeneca Plc 27

Avesthagen Limited 28

Avexxin AS 29

BIOCAD 30

Biocon Limited 31

Bionovis SA 32

Can-Fite BioPharma Ltd. 33

Celgene Corporation 34

Celltrion, Inc. 35

Creabilis SA 36

Delenex Therapeutics AG 37

Dermira Inc. 38

Epirus Biopharmaceuticals, Inc. 39

Forward Pharma A/S 40

Galectin Therapeutics, Inc. 41

Genor BioPharma Co., Ltd. 42

GlaxoSmithKline Plc 43

Hetero Drugs Limited 44

Idera Pharmaceuticals, Inc. 45

Invion Limited 46

Johnson & Johnson 47

Kadmon Corporation, LLC 48

Kineta, Inc. 49

Kyowa Hakko Kirin Co., Ltd. 50

LEO Pharma A/S 51

Lipidor AB 52

Mabion SA 53

Mabtech Limited 54

Maruho Co., Ltd. 55

Momenta Pharmaceuticals, Inc. 56

Mycenax Biotech Inc. 57

Oncobiologics, Inc. 58

Pfizer Inc. 59

Promius Pharma, LLC 60

Protalix BioTherapeutics, Inc. 61

Provectus Biopharmaceuticals, Inc. 62

R-Tech Ueno, Ltd. 63

TetraLogic Pharmaceuticals 64

Therapeutic Proteins International, LLC 65

UCB S.A. 66

Valeant Pharmaceuticals International, Inc. 67

Plaque Psoriasis (Psoriasis Vulgaris)-Therapeutics Assessment 68

Assessment by Monotherapy Products 68

Assessment by Combination Products 69

Assessment by Target 70

Assessment by Mechanism of Action 74

Assessment by Route of Administration 77

Assessment by Molecule Type 79

Drug Profiles 81

(betamethasone dipropionate + calcipotriene)-Drug Profile 81

(calcipotriene + betamethasone dipropionate)-Drug Profile 82

(calcipotriene + betamethasone)-Drug Profile 84

adalimumab biosimilar-Drug Profile 85

adalimumab biosimilar-Drug Profile 86

adalimumab biosimilar-Drug Profile 87

adalimumab biosimilar-Drug Profile 88

adalimumab biosimilar-Drug Profile 89

adalimumab biosimilar-Drug Profile 90

adalimumab biosimilar-Drug Profile 91

adalimumab biosimilar-Drug Profile 92

adalimumab biosimilar-Drug Profile 93

adalimumab biosimilar-Drug Profile 94

adalimumab biosimilar-Drug Profile 95

adalimumab biosimilar-Drug Profile 96

adalimumab biosimilar-Drug Profile 97

adalimumab biosimilar-Drug Profile 98

AM-001-Drug Profile 99

AVX-001-Drug Profile 100

betamethasone valerate + maxacalcitol-Drug Profile 101

bimekizumab-Drug Profile 102

bleselumab-Drug Profile 103

brodalumab-Drug Profile 104

calcipotriene-Drug Profile 106

CC-90005-Drug Profile 107

CT-327-Drug Profile 108

dalazatide-Drug Profile 110

DFD-01-Drug Profile 112

DFD-06-Drug Profile 113

dimethyl fumarate-Drug Profile 114

DLX-105-Drug Profile 115

DNX-114-Drug Profile 117

DNX-514-Drug Profile 118

DRM-02-Drug Profile 119

etanercept biosimilar-Drug Profile 120

etanercept biosimilar-Drug Profile 121

etanercept biosimilar-Drug Profile 122

etanercept biosimilar-Drug Profile 123

etanercept biosimilar-Drug Profile 124

GK-664S-Drug Profile 125

GRMD-02-Drug Profile 126

GSK-2981278-Drug Profile 129

guselkumab-Drug Profile 130

IDP-118-Drug Profile 133

IDP-122-Drug Profile 134

IMO-8400-Drug Profile 135

IMP-731-Drug Profile 137

infliximab biobetter-Drug Profile 138

infliximab biosimilar-Drug Profile 139

infliximab biosimilar-Drug Profile 141

infliximab biosimilar-Drug Profile 143

infliximab biosimilar-Drug Profile 144

INV-103-Drug Profile 145

KD-025-Drug Profile 147

LEO-32731-Drug Profile 149

LP-0113-Drug Profile 150

M-7040-Drug Profile 151

MOL-4239-Drug Profile 152

MOL-4249-Drug Profile 153

pefcalcitol-Drug Profile 154

PF-04965842-Drug Profile 156

PF-06700841-Drug Profile 157

PH-10-Drug Profile 158

piclidenoson-Drug Profile 160

RTU-1096-Drug Profile 162

SHP-141-Drug Profile 163

tofacitinib-Drug Profile 165

toreforant tartrate-Drug Profile 169

UCB-5857-Drug Profile 171

ustekinumab biosimilar-Drug Profile 172

Plaque Psoriasis (Psoriasis Vulgaris)-Recent Pipeline Updates 173

Plaque Psoriasis (Psoriasis Vulgaris)-Dormant Projects 229

Plaque Psoriasis (Psoriasis Vulgaris)-Discontinued Products 234

Plaque Psoriasis (Psoriasis Vulgaris)-Product Development Milestones 235

Featured News & Press Releases 235

Appendix 243

Methodology 243

Coverage 243

Secondary Research 243

Primary Research 243

Expert Panel Validation 243

Contact Us 243

Disclaimer 244

List of Tables

Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2015 16

Number of Products under Development by Companies, H2 2015 18

Number of Products under Development by Companies, H2 2015 (Contd..1) 19

Number of Products under Development by Companies, H2 2015 (Contd..2) 20

Comparative Analysis by Late Stage Development, H2 2015 21

Comparative Analysis by Clinical Stage Development, H2 2015 22

Comparative Analysis by Early Stage Development, H2 2015 23

Comparative Analysis by Unknown Stage Development, H2 2015 24

Products under Development by Companies, H2 2015 25

Products under Development by Companies, H2 2015 (Contd..1) 26

Products under Development by Companies, H2 2015 (Contd..2) 27

Products under Development by Companies, H2 2015 (Contd..3) 28

Products under Development by Companies, H2 2015 (Contd..4) 29

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by 3SBio Inc., H2 2015 30

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Amgen Inc., H2 2015 31

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by AstraZeneca Plc, H2 2015 32

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Avesthagen Limited, H2 2015 33

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Avexxin AS, H2 2015 34

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by BIOCAD, H2 2015 35

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Biocon Limited, H2 2015 36

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Bionovis SA, H2 2015 37

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Can-Fite BioPharma Ltd., H2 2015 38

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Celgene Corporation, H2 2015 39

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Celltrion, Inc., H2 2015 40

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Creabilis SA, H2 2015 41

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Delenex Therapeutics AG, H2 2015 42

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Dermira Inc., H2 2015 43

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 44

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Forward Pharma A/S, H2 2015 45

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Galectin Therapeutics, Inc., H2 2015 46

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Genor BioPharma Co., Ltd., H2 2015 47

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by GlaxoSmithKline Plc, H2 2015 48

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Hetero Drugs Limited, H2 2015 49

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Idera Pharmaceuticals, Inc., H2 2015 50

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Invion Limited, H2 2015 51

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Johnson & Johnson, H2 2015 52

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Kadmon Corporation, LLC, H2 2015 53

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Kineta, Inc., H2 2015 54

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015 55

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by LEO Pharma A/S, H2 2015 56

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Lipidor AB, H2 2015 57

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Mabion SA, H2 2015 58

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Mabtech Limited, H2 2015 59

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Maruho Co., Ltd., H2 2015 60

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Momenta Pharmaceuticals, Inc., H2 2015 61

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Mycenax Biotech Inc., H2 2015 62

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Oncobiologics, Inc., H2 2015 63

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Pfizer Inc., H2 2015 64

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Promius Pharma, LLC, H2 2015 65

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Protalix BioTherapeutics, Inc., H2 2015 66

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Provectus Biopharmaceuticals, Inc., H2 2015 67

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by R-Tech Ueno, Ltd., H2 2015 68

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by TetraLogic Pharmaceuticals, H2 2015 69

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Therapeutic Proteins International, LLC, H2 2015 70

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by UCB S.A., H2 2015 71

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015 72

Assessment by Monotherapy Products, H2 2015 73

Assessment by Combination Products, H2 2015 74

Number of Products by Stage and Target, H2 2015 76

Number of Products by Stage and Mechanism of Action, H2 2015 80

Number of Products by Stage and Route of Administration, H2 2015 83

Number of Products by Stage and Molecule Type, H2 2015 85

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics-Recent Pipeline Updates, H2 2015 178

Plaque Psoriasis (Psoriasis Vulgaris)-Dormant Projects, H2 2015 234

Plaque Psoriasis (Psoriasis Vulgaris)-Dormant Projects (Contd..1), H2 2015 235

Plaque Psoriasis (Psoriasis Vulgaris)-Dormant Projects (Contd..2), H2 2015 236

Plaque Psoriasis (Psoriasis Vulgaris)-Dormant Projects (Contd..3), H2 2015 237

Plaque Psoriasis (Psoriasis Vulgaris)-Dormant Projects (Contd..4), H2 2015 238

Plaque Psoriasis (Psoriasis Vulgaris)-Discontinued Products, H2 2015 239

List of Figures

Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2015 16

Number of Products under Development by Companies, H2 2015 17

Comparative Analysis by Late Stage Development, H2 2015 21

Comparative Analysis by Clinical Stage Development, H2 2015 22

Comparative Analysis by Early Stage Products, H2 2015 23

Assessment by Monotherapy Products, H2 2015 73

Assessment by Combination Products, H2 2015 74

Number of Products by Top 10 Targets, H2 2015 75

Number of Products by Stage and Top 10 Targets, H2 2015 75

Number of Products by Top 10 Mechanism of Actions, H2 2015 79

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 79

Number of Products by Routes of Administration, H2 2015 82

Number of Products by Stage and Routes of Administration, H2 2015 82

Number of Products by Molecule Types, H2 2015 84

Number of Products by Stage and Molecule Types, H2 2015 84

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3SBio Inc.

Amgen Inc.

AstraZeneca Plc

Avesthagen Limited

Avexxin AS

BIOCAD

Biocon Limited

Bionovis SA

Can-Fite BioPharma Ltd.

Celgene Corporation

Celltrion, Inc.

Creabilis SA

Delenex Therapeutics AG

Dermira Inc.

Epirus Biopharmaceuticals, Inc.

Forward Pharma A/S

Galectin Therapeutics, Inc.

Genor BioPharma Co., Ltd.

GlaxoSmithKline Plc

Hetero Drugs Limited

Idera Pharmaceuticals, Inc.

Invion Limited

Johnson & Johnson

Kadmon Corporation, LLC

Kineta, Inc.

Kyowa Hakko Kirin Co., Ltd.

LEO Pharma A/S

Lipidor AB

Mabion SA

Mabtech Limited

Maruho Co., Ltd.

Momenta Pharmaceuticals, Inc.

Mycenax Biotech Inc.

Oncobiologics, Inc.

Pfizer Inc.

Promius Pharma, LLC

Protalix BioTherapeutics, Inc.

Provectus Biopharmaceuticals, Inc.

R-Tech Ueno, Ltd.

TetraLogic Pharmaceuticals

Therapeutic Proteins International, LLC

UCB S.A.

Valeant Pharmaceuticals International, Inc.

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutic Products under Development, Key Players in Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Plaque Psoriasis (Psoriasis Vulgaris) Pipeline Overview, Plaque Psoriasis (Psoriasis Vulgaris) Pipeline, Plaque Psoriasis (Psoriasis Vulgaris) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com